GHK-Cu

1. Overview

GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring tripeptide-copper complex first identified in human plasma by Loren Pickart and Marguerite Thaler in 1973 [1]. The researchers observed that a factor in young human plasma (age 20-25) could stimulate aged liver tissue to synthesize proteins in a pattern resembling that of younger tissue. This factor was subsequently isolated and identified as the tripeptide glycyl-L-histidyl-L-lysine bound to a copper(II) ion [1].

GHK-Cu is present in human plasma, saliva, and urine. Plasma concentrations have been measured at approximately 200 ng/mL in individuals around age 20, declining to approximately 80 ng/mL by age 60 [6][8]. This age-related decline has led researchers to hypothesize that diminishing GHK-Cu levels may contribute to the reduced regenerative capacity observed in aging tissues.

The peptide has attracted research interest for its roles in collagen synthesis, wound healing, anti-inflammatory signaling, and gene expression modulation. Its most commercially developed application is in topical skincare formulations, where it is marketed as Copper Tripeptide-1.

Molecular Weight

403.93 g/mol

Sequence

Gly-His-Lys + Cu²⁺

Half-life

~1-2 hours in plasma

Routes Studied

Topical (cream/serum), subcutaneous injection

FDA Status

Not regulated as drug for topical cosmetic use. Not approved for injectable use.

WADA Status

Not specifically listed

2. Mechanism of Action

GHK-Cu exerts biological effects through multiple mechanisms, many of which appear to be linked to its copper-binding properties and its interaction with extracellular matrix components.

Copper Ion Delivery

The tripeptide GHK has a high affinity for copper(II) ions (log K = 16.44) and is thought to function in part as a copper delivery vehicle [6]. Copper is a cofactor for several enzymes critical to tissue repair, including lysyl oxidase (essential for collagen and elastin cross-linking), superoxide dismutase (antioxidant defense), and cytochrome c oxidase (cellular respiration) [6][8].

Collagen and Extracellular Matrix Synthesis

GHK-Cu has been shown to stimulate synthesis of collagen types I and III in fibroblast cultures [2]. Maquart et al. (1993, 1999) demonstrated that GHK-Cu also promotes production of decorin, dermatan sulfate, chondroitin sulfate, and glycosaminoglycans in vivo [3][4]. These extracellular matrix components are essential for tissue structure and wound repair.

Gene Expression Modulation

A large-scale gene expression analysis by Pickart et al. (2012) using the Broad Institute's Connectivity Map data found that GHK modulates the expression of 4,048 human genes, representing approximately 31.2% of the human genome [7]. The affected genes included those involved in:

• Tissue remodeling and extracellular matrix synthesis (upregulated)
• Antioxidant defense pathways (upregulated)
• Pro-inflammatory cytokine signaling (downregulated)
• DNA repair mechanisms (upregulated)
• Ubiquitin-proteasome pathways (modulated)

The breadth of gene expression changes suggests that GHK-Cu may act through fundamental regulatory pathways rather than through a single receptor-mediated mechanism [7][8].

Anti-inflammatory Activity

GHK-Cu has been reported to suppress expression of pro-inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in several experimental systems [6][8]. It has also been observed to reduce oxidative damage markers, potentially through upregulation of antioxidant enzymes [8].

3. Pharmacokinetics

Plasma Levels and Age-Related Decline

GHK is present endogenously in human plasma as part of the body's natural tissue maintenance system. Pickart's research established that circulating GHK levels undergo a significant age-related decline: from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60, representing a roughly 60% reduction over four decades [6][8]. This decline closely parallels the age-related decrease in wound healing capacity, collagen synthesis, and tissue regenerative potential observed clinically. The loss of endogenous GHK may represent one of the molecular underpinnings of skin aging and diminished repair capacity in older adults.

Plasma Half-Life and Degradation

Free GHK-Cu has a short plasma half-life, estimated at minutes to approximately 1-2 hours depending on measurement methodology [6][8]. The peptide is rapidly degraded by serum peptidases, particularly aminopeptidases that cleave the glycine residue from the N-terminus. This rapid degradation limits systemic bioavailability after any route of administration and is one rationale for the focus on topical delivery, where local tissue concentrations can be maintained.

Copper Release Kinetics

GHK binds copper(II) with a conditional stability constant (log K = 16.44 at physiological pH), which represents a moderate-to-high affinity [6]. This is biologically significant because it is strong enough to carry copper efficiently through extracellular fluids, yet sufficiently labile to release copper to higher-affinity sites such as the active centers of copper-dependent enzymes (superoxide dismutase, lysyl oxidase, cytochrome c oxidase). The copper exchange is thought to be a key element of GHK-Cu's mechanism: the tripeptide acts as a shuttle, delivering copper ions to cells and enzymes that require them for catalytic function.

Topical Penetration and Dermal Absorption

Topical absorption of GHK-Cu has been studied using Franz diffusion cells and excised skin models [12]. As a small, charged tripeptide (MW 403.93 g/mol), GHK-Cu faces moderate barriers to passive diffusion across the stratum corneum. Penetration studies indicate that:

• Stratum corneum: GHK-Cu can penetrate the outermost barrier to a limited degree in its free form. Formulation vehicles significantly affect penetration depth; liposomal and microemulsion carriers enhance passage through the stratum corneum by 2- to 4-fold compared to simple aqueous solutions [12].
• Viable epidermis and dermis: Once past the stratum corneum, GHK-Cu reaches the viable epidermis and upper dermis where target fibroblasts reside. Studies using fluorescently labeled GHK have confirmed dermal delivery, particularly with occlusive application or lipid-based carriers.
• Subcutaneous absorption: When injected subcutaneously (studied in animal models), GHK-Cu enters the local tissue rapidly but systemic distribution is limited by rapid peptidase degradation. Local tissue concentrations at the injection site are substantially higher than achievable by topical application [3].

Formulation Stability

GHK-Cu presents stability challenges in formulation. The copper(II) complex is susceptible to reduction (Cu²⁺ to Cu⁺) in the presence of ascorbic acid and other common cosmetic antioxidants, which can disrupt the peptide-copper binding. The free peptide is also prone to oxidation and degradation at extremes of pH. Optimal formulation stability is achieved at pH 5.0-6.5 in the absence of strong reducing agents. Lyophilized GHK-Cu powder is stable long-term when stored desiccated below 25°C. In solution, stability is best maintained in copper-saturated conditions with appropriate buffering, with shelf-life data supporting 12-24 months in well-formulated cosmetic products stored at ambient temperature [12][15].

4. Researched Applications

Critical Distinction: Topical vs. Injectable/Systemic Evidence

The evidence base for GHK-Cu differs dramatically depending on the route of administration:

• Topical GHK-Cu (strong evidence, 40+ years of commercial use): Multiple controlled human trials support the efficacy of topical GHK-Cu for skin remodeling, wrinkle reduction, and improved skin firmness [5][9]. Copper peptide-containing skincare products have been commercially available since the early 1990s (Skin Biology, Neova, and numerous subsequent brands), with an extensive post-market safety record spanning over three decades. The CIR Expert Panel has assessed topical GHK-Cu as safe [11].
• Injectable/systemic GHK-Cu (minimal evidence): There are NO published controlled human clinical trials of injectable (subcutaneous, intramuscular, or intravenous) GHK-Cu. All injectable evidence is limited to animal wound models [3][10]. The rapid plasma degradation (half-life of minutes to 1-2 hours) limits systemic bioavailability, and no pharmacokinetic data for injectable GHK-Cu in humans have been published. Individuals using injectable GHK-Cu are operating entirely outside the published evidence base.

IWGDF 2024 Wound Healing Guidelines: The International Working Group on the Diabetic Foot (IWGDF) 2024 guidelines do NOT recommend GHK-Cu for diabetic wound healing. Despite preclinical promise, the absence of controlled human wound healing trials with GHK-Cu means it has not met the evidence threshold for inclusion in international wound care guidelines.

Wound Healing

Wound healing was among the earliest studied applications of GHK-Cu. Maquart et al. (1993) showed that GHK-Cu incorporated into collagen sponges significantly increased collagen synthesis, glycosaminoglycan production, and DNA synthesis in rat wound models [3]. Canapp et al. (2003) reported that topical GHK-Cu improved wound healing in a canine model, with treated wounds demonstrating faster closure, increased tensile strength, and higher collagen content [10].

Skin Remodeling and Anti-Aging

The most commercially developed application of GHK-Cu is in topical skincare formulations. Abdulghani et al. (1998) reported that a topical copper peptide cream improved skin appearance and increased dermal thickness in photodamaged facial skin over 12 weeks [9]. Leyden et al. (2002) conducted a controlled trial in 67 women aged 41-62 and found that GHK-Cu cream improved skin laxity, clarity, and firmness and reduced fine lines and wrinkles when compared to both placebo and vitamin C cream [5].

These effects are thought to result from stimulation of collagen and glycosaminoglycan synthesis in dermal fibroblasts, leading to increased dermal thickness and improved skin architecture [6].

Bone and Cartilage Repair

Preclinical studies have suggested that GHK-Cu may promote bone repair by stimulating osteoblast activity and modulating transforming growth factor-β (TGF-β) signaling [6][8]. However, controlled clinical data in orthopedic applications are not yet available.

Hair Follicle Support

GHK-Cu has been studied for potential effects on hair follicles, with in vitro research suggesting it may increase follicle size and proliferation of follicular cells [6]. Pyo et al. (2007) demonstrated that GHK-Cu at micromolar concentrations increased human hair follicle cell proliferation and promoted expression of hair growth-associated genes in vitro [17]. Earlier work by Uno and Kurata (1993) showed that copper peptides could enlarge miniaturized follicles in organ culture models [18]. Some cosmetic products incorporate copper peptides for hair-related claims, though robust clinical evidence for hair regrowth in humans remains limited.

Anti-Inflammatory and Colitis Research (2025)

A 2025 study published in Frontiers in Pharmacology evaluated GHK-Cu's therapeutic potential in a dextran sulfate sodium (DSS)-induced murine model of ulcerative colitis [19]. GHK-Cu alleviated weight loss, improved the disease activity index, reduced colonic edema and shortening, attenuated inflammatory damage, increased goblet cell numbers, and suppressed inflammatory cytokines (TNF-alpha, IL-6, IL-1beta). Network pharmacology and molecular docking identified SIRT1 as a potential target, with GHK-Cu facilitating mucosal healing through SIRT1/STAT3 pathway regulation. A co-culture system demonstrated that GHK-Cu promoted epithelial cell healing by upregulating tight junction proteins ZO-1 and Occludin [19]. This represents the first preclinical evidence of GHK-Cu's therapeutic potential in inflammatory bowel disease.

Neuroprotection and Cognitive Function

Gene expression analyses have identified modulation of genes related to nervous system function, and some researchers have proposed that GHK-Cu may have neuroprotective properties [7][8]. This remains a speculative area with no clinical data currently available.

5. Dose-Response Relationships

Optimal Concentrations by Application

Research across multiple experimental systems has identified concentration ranges associated with maximal biological effects for GHK-Cu:

• Wound healing: In the Maquart et al. rat wound studies, a dose of 0.5 µg per wound site (in collagen sponge) was effective [3]. In vitro fibroblast stimulation studies have typically used concentrations in the range of 10⁻⁹ to 10⁻⁶ M (approximately 0.0004 to 0.4 µg/mL), with maximal collagen synthesis stimulation observed around 10⁻⁸ to 10⁻⁷ M [2][6].
• Cosmetic anti-aging (topical): Commercial formulations typically contain GHK-Cu at 0.01% to 0.1% (w/v). The clinical trials by Leyden et al. and Abdulghani et al. used proprietary concentrations in this range [5][9]. Higher concentrations do not necessarily yield better outcomes due to the bell-shaped dose-response curve (see below).
• Hair growth: In vitro studies by Pyo et al. used concentrations of 1-10 µM, with proliferative effects on dermal papilla cells peaking near 1 µM [17].

Bell-Shaped Dose-Response Curve

A notable feature of GHK-Cu pharmacology is its bell-shaped (biphasic or hormetic) dose-response curve [6][8]. At very low concentrations (sub-nanomolar), effects are minimal. Biological activity increases through the nanomolar range, peaks at an optimal concentration window (typically 10⁻⁹ to 10⁻⁷ M depending on the assay), and then diminishes or reverses at higher concentrations (above 10⁻⁵ M). At supraphysiological concentrations, GHK-Cu may paradoxically inhibit fibroblast proliferation or collagen synthesis, likely due to copper overload or competitive inhibition at binding sites. This bell-shaped response is consistent with GHK-Cu's role as a physiological modulator rather than a pharmacological agonist, and it underscores the importance of using appropriately formulated concentrations rather than assuming that higher doses are more effective.

Topical vs. Injectable Efficacy

Direct comparisons between topical and injectable routes in the same study design are not available. However, the available data allow some observations:

• Topical: Proven effective in multiple controlled human trials for skin remodeling, with 12-week treatment courses producing measurable improvements in skin thickness, firmness, and fine lines [5][9]. Limited by penetration through the stratum corneum, so effects are largely confined to the epidermis and upper dermis.
• Injectable (subcutaneous): Studied in animal wound models, where it produces robust local effects including increased collagen deposition and accelerated wound closure [3][10]. Delivers higher local concentrations directly to the dermis and subcutis, bypassing the epidermal barrier. However, systemic effects are limited by rapid plasma degradation.

In practice, topical application is the established route for cosmetic and skin-remodeling indications, while injectable routes remain experimental and primarily limited to preclinical wound healing research.

6. Clinical Evidence Summary

Clinical evidence for GHK-Cu is most developed in the area of topical skin applications, where several controlled studies have been conducted. For other applications, evidence remains largely preclinical.

7. Dosing in Research

Dosing for GHK-Cu varies by application route. Topical formulations have been the most studied in humans. The following reflects doses reported in published research and are not recommendations for human use.

8. Safety and Side Effects

GHK-Cu has a generally favorable safety profile in published research. As a naturally occurring peptide present in human plasma, it is considered to have low inherent toxicity at physiological concentrations [6][8].

CIR Safety Assessment

The Cosmetic Ingredient Review (CIR) Expert Panel evaluated the safety of Copper Tripeptide-1 (GHK-Cu) for use in cosmetic formulations [11]. The panel reviewed available toxicological data including dermal irritation, sensitization, phototoxicity, and genotoxicity studies. The CIR assessment concluded that GHK-Cu is safe as used in cosmetic products at the concentrations found in current commercial formulations (typically up to 0.1%). The panel noted the absence of significant irritation or sensitization signals in the available data and the peptide's status as a naturally occurring component of human plasma as favorable safety indicators.

Clinical Tolerability

In clinical trials of topical formulations, GHK-Cu creams and serums were reported to be well-tolerated, with no serious adverse events documented [5][9]. Mild skin irritation has been reported in some users of copper peptide-containing cosmetics, though this may relate to the formulation base rather than the peptide itself. Allergic contact dermatitis to GHK-Cu itself appears rare; sensitization rates in patch testing studies have been negligible. The overall tolerability profile of topical GHK-Cu is favorable compared to retinoids, which frequently cause irritation, dryness, and photosensitivity, particularly during the initial weeks of use.

Cytotoxicity Thresholds

In vitro cytotoxicity studies on fibroblasts and keratinocytes have demonstrated that GHK-Cu is non-cytotoxic at concentrations up to approximately 10⁻⁵ M (roughly 4 µg/mL) [6]. Above this concentration, cell viability may decline, consistent with the bell-shaped dose-response profile. This cytotoxicity threshold is well above the concentrations used in cosmetic formulations and the endogenous plasma levels of the peptide.

Copper Toxicity Considerations

While GHK-Cu delivers copper in a controlled, chelated form, excessive copper exposure remains a theoretical concern at very high doses or with prolonged parenteral administration. Copper overload can generate reactive oxygen species via Fenton-like chemistry, potentially causing oxidative damage to lipids, proteins, and DNA. In practice, the amount of copper delivered by topical GHK-Cu products is orders of magnitude below levels associated with systemic copper toxicity. However, individuals with copper metabolism disorders such as Wilson disease (impaired hepatic copper excretion) or Menkes disease should avoid exogenous copper peptide products. For injectable use, copper load must be carefully considered, particularly with repeated dosing, although the microgram quantities typically used in preclinical studies are far below toxic thresholds [8].

Long-Term Safety

Long-term safety data for GHK-Cu derive primarily from decades of cosmetic use rather than from formal long-term clinical trials. Copper peptide-containing skincare products have been on the market since the 1990s (notably the Skin Biology and Neova product lines), and no pattern of delayed adverse effects has emerged from post-market surveillance or consumer reporting databases. This extensive consumer use history, while not equivalent to controlled long-term studies, provides reasonable confidence in the safety of topical GHK-Cu at cosmetic concentrations for continuous use.

Safety data for injectable GHK-Cu in humans are limited. While subcutaneous injection has been studied in animal models, no large-scale human safety trials of injectable GHK-Cu have been published [8].

9. Comparative Effectiveness

GHK-Cu vs. Retinoids (Tretinoin) for Anti-Aging

Retinoids remain the gold standard for topical anti-aging with the strongest evidence base. Head-to-head comparisons are limited, but several studies provide indirect comparison data:

• Efficacy: Abdulghani et al. (1998) compared a copper peptide cream against tretinoin and vitamin C cream and found that the copper peptide cream increased skin thickness comparably to tretinoin over 12 weeks [9]. Kang et al. (2007) compared copper peptide cream to tretinoin 0.025% emollient cream and reported similar improvement in clinical photoaging scores, though tretinoin showed a slight edge in collagen fiber density on histological analysis [13].
• Tolerability: GHK-Cu has a significant tolerability advantage. Retinoids commonly cause erythema, peeling, dryness, and photosensitivity (the "retinoid dermatitis" that affects 50-80% of new users). GHK-Cu formulations produce virtually no irritation, making them suitable for sensitive skin types and as an alternative for patients who cannot tolerate retinoids [5][13][15].
• Mechanism: Retinoids act primarily through nuclear retinoic acid receptors (RARs/RXRs) to upregulate collagen synthesis and accelerate cell turnover. GHK-Cu works through copper delivery, ECM remodeling, and broad gene expression modulation. The mechanisms are complementary and non-overlapping, which has led some dermatologists to recommend combination use.

GHK-Cu vs. Vitamin C (L-Ascorbic Acid) for Collagen Synthesis

Both GHK-Cu and vitamin C promote collagen synthesis but through distinct mechanisms:

• Vitamin C is an essential cofactor for prolyl hydroxylase and lysyl hydroxylase, enzymes required for collagen post-translational modification and proper triple helix formation. Without adequate vitamin C, collagen is structurally defective. Topical vitamin C (typically 10-20% L-ascorbic acid) has robust evidence for photoprotection and collagen stimulation.
• GHK-Cu stimulates collagen gene transcription and also delivers copper for lysyl oxidase, the enzyme responsible for collagen cross-linking. In the Leyden et al. (2002) trial, GHK-Cu cream outperformed vitamin C cream in improving skin laxity and reducing fine lines [5].
• Formulation compatibility: GHK-Cu and L-ascorbic acid are generally incompatible in the same formulation because ascorbic acid can reduce Cu²⁺ to Cu⁺, disrupting the GHK-copper complex and potentially generating free radicals. They are best used at separate times (e.g., vitamin C in the morning, GHK-Cu in the evening).

GHK-Cu vs. Matrixyl (Palmitoyl Pentapeptide-4) and Argireline (Acetyl Hexapeptide-3) for Wrinkles

• Matrixyl is a synthetic matrikine fragment (Lys-Thr-Thr-Lys-Ser, palmitoylated) that stimulates collagen and fibronectin synthesis. It has clinical evidence for wrinkle reduction, but acts through a narrower set of pathways (primarily stimulating TGF-β signaling) compared to GHK-Cu's modulation of over 4,000 genes [7][15].
• Argireline is a hexapeptide that acts as a mild neuromuscular junction inhibitor (SNAP-25 fragment mimic), reducing muscle contraction-related wrinkles. Its mechanism is fundamentally different from GHK-Cu's matrix-remodeling approach. Argireline addresses expression lines; GHK-Cu addresses structural skin aging. The two may be used complementarily.
• Differentiator: GHK-Cu's modulation of 4,048 genes (Broad Institute Connectivity Map data [7][16]) sets it apart from all other cosmetic peptides, which typically affect only a handful of pathways. This breadth of activity means GHK-Cu simultaneously addresses collagen synthesis, inflammation, antioxidant defense, and DNA repair, representing a fundamentally different and broader mechanism than any single-target peptide.

GHK-Cu vs. Minoxidil for Hair Growth

• Minoxidil (2-5% topical) is the only FDA-approved topical treatment for androgenetic alopecia and has strong clinical trial evidence demonstrating hair regrowth in both men and women.
• GHK-Cu has limited hair growth evidence. In vitro, Pyo et al. (2007) showed that GHK-Cu stimulated proliferation of human dermal papilla cells and increased expression of vascular endothelial growth factor (VEGF) in hair follicles [17]. Uno and Kurata (1993) demonstrated follicle enlargement in organ culture with copper peptides [18]. However, no rigorous human clinical trials have compared GHK-Cu to minoxidil for hair regrowth outcomes.
• Current standing: Minoxidil has vastly stronger clinical evidence for hair growth. GHK-Cu's potential role may be as an adjunctive agent supporting scalp skin health and follicle microenvironment rather than as a primary hair growth treatment.

GHK-Cu vs. AHK-Cu (Alanyl-Histidyl-Lysine:Copper)

AHK-Cu is a related copper tripeptide (Ala-His-Lys:Cu²⁺) that has been investigated primarily for hair growth applications. In vitro studies suggest AHK-Cu may be more potent than GHK-Cu specifically for stimulating dermal papilla cell proliferation. However, AHK-Cu lacks the extensive gene expression, wound healing, and skin remodeling data that GHK-Cu possesses. GHK-Cu remains the far more broadly researched and clinically validated copper peptide, with its 4,000+ gene expression profile [7] representing a unique and unreplicated differentiator in the peptide landscape. AHK-Cu's evidence base is limited to a small number of in vitro hair follicle studies without human clinical confirmation.

The 4,000+ Gene Expression Profile as a Unique Differentiator

The 2012 analysis by Pickart et al. using the Broad Institute's Connectivity Map (CMap) database [7][16] remains one of the most striking findings in cosmetic peptide research. GHK was shown to modulate the expression of 4,048 human genes, affecting pathways across tissue remodeling (collagen, elastin, glycosaminoglycans), antioxidant defense (SOD, glutathione system), anti-inflammation (IL-6, TNF-α suppression), DNA repair, apoptosis regulation, and ubiquitin-proteasome function. No other cosmetic peptide or small molecule has demonstrated a gene expression profile of comparable breadth. This comprehensive action profile positions GHK-Cu not as a single-target active ingredient but as a systemic tissue maintenance signal, consistent with its endogenous role as a circulating regenerative factor whose decline with age correlates with the onset of aging-related tissue degeneration [8].

10. Regulatory Status

GHK-Cu occupies an unusual regulatory position. As a cosmetic ingredient (listed as Copper Tripeptide-1 in the International Nomenclature of Cosmetic Ingredients), it is widely available in topical skincare products and is not subject to pharmaceutical regulation in that context.

GHK-Cu has not received FDA approval as a drug for any indication. Injectable formulations are not approved for human use in any major regulatory jurisdiction.

The peptide is not specifically listed on the World Anti-Doping Agency (WADA) prohibited list, unlike some other peptides studied for tissue repair.

11. Related Peptides

See also: Epithalon, TB-500

12. References

1. [1] Pickart L, Thaler MM (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. DOI PubMed
2. [2] Maquart FX, Pickart L, Laurent M, et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. DOI PubMed
3. [3] Maquart FX, Bellon G, Chaqour B, et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation. DOI PubMed
4. [4] Maquart FX, Siméon A, Pira S, et al. (1999). Regulation of cell activity by the extracellular matrix: the concept of matrikines. Journal of the Society of Biology. PubMed
5. [5] Leyden JJ, Stevens T, Finkey MB, Barkovic S (2002). Skin care benefits of copper peptide containing facial cream. American Academy of Dermatology 60th Annual Meeting. PubMed
6. [6] Pickart L, Vasquez-Soltero JM, Margolina A (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. DOI PubMed
7. [7] Pickart L, Vasquez-Soltero JM, Margolina A (2012). GHK and DNA: resetting the human genome to health. BioMed Research International. DOI PubMed
8. [8] Pickart L, Margolina A (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. DOI PubMed
9. [9] Abdulghani AA, Sherr S, Shirin S, et al. (1998). Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin. Disease Management and Clinical Outcomes. PubMed
10. [10] Canapp SO, Farese JP, Schultz GS, et al. (2003). The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery. DOI PubMed
11. [11] Cosmetic Ingredient Review (CIR) Expert Panel (2015). Safety assessment of Copper Tripeptide-1 as used in cosmetics. International Journal of Toxicology. DOI
12. [12] Badenhorst T, Svirskis D, Valentijn-Benz M, et al. (2014). Stability and permeation studies of GHK-Cu through skin. Journal of Pharmaceutical Sciences.
13. [13] Kang YA, Daryanani HA, Kundu RV, et al. (2007). Tretinoin emollient cream vs copper peptide cream for photoaged skin. Journal of Cosmetic Dermatology. PubMed
14. [14] Hussain M, Goldberg DJ (2007). Topical copper tripeptide and tretinoin for facial skin rejuvenation. Journal of Drugs in Dermatology.
15. [15] Gorouhi F, Maibach HI (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science. DOI PubMed
16. [16] Lamb JL, Crawford ED, Peck D, et al. (2006). The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. DOI PubMed
17. [17] Pyo HK, Yoo HG, Won CH, et al. (2007). The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. PubMed
18. [18] Uno H, Kurata S (1993). Chemical agents and peptides affect hair growth. Journal of Investigative Dermatology. PubMed
19. [19] Mao J, Huang X, Li Y, Sun L, Zhang H, Cheng K, Zeng Q, Lei R, Wang S, Yao J (2025). Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Frontiers in Pharmacology. DOI PubMed